CDK4/6 inhibitors, approved by the FDA in 2015 for the first-line treatment of HR(+)/HER2 (–) advanced breast cancer (15), primarily inhibit the phosphorylation of the retinoblastoma gene (Rb), blocking the G1 phase of the cell cycle in tumor cells (16). This evidence concerns the gene RB1 and neoplasm.